TABLE 5.
Synthesis of IFN-γ by T-cell subsets
| Phenotype | T cells synthesizing IFN-γa
|
|||||
|---|---|---|---|---|---|---|
| Control subjects
|
MF
|
SS
|
||||
| % | Count/μl | % | Count/μl | % | Count/μl | |
| Total CD3+b | 36.4 (3.7) | 519 (67) | 28.6 (3.0) | 238 (35) | 8.4 (2.3)c | 102 (21) |
| CD3+ CD7+b | 34.9 (3.4) | 430 (56) | 25.7 (2.7) | 194 (31) | 21.8 (4.1) | 76 (25) |
| CD3+ CD7− | 60.5 (2.2) | 79 (15) | 49.6 (5.1) | 42 (7) | 9.9 (4.1)c | 52 (11) |
| CD3+ CD4+ | 25.9 (7.1) | 201 (30)d | 24.0 (4.7) | 110 (22) | 4.6 (0.8)e | 108 (45) |
| CD3+ CD8+ | 46.6 (5.0) | 216 (35) | 37.6 (6.5) | 243 (33) | 52.3 (11.2) | 46 (11)f |
a
Figures represent means ± standard errors of the mean (in parentheses).
b
There were significant differences between the three study groups with respect to the number of IFN-γ+ CD3+ T cells and IFN-γ+ CD7+ T-cell subsets.
c
Patients with SS had significantly lower percentages of IFN-γ+ CD3+ T cells and of IFN-γ+ CD7− T cells than patients with MF and controls.
d
Control subjects had significantly higher numbers of IFN-γ+ CD4+ T cells than patients with MF or SS.
e
Patients with SS had significantly lower percentages of IFN-γ+ CD4+ T cells than patients with MF and controls.
f
Patients with SS had significantly lower numbers of IFN-γ+ CD8+ T cells than patients with MF and controls.